Literature DB >> 11267167

Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine.

C Ponticelli1, A Yussim, V Cambi, C Legendre, G Rizzo, M Salvadori, D Kahn, S H Kashi, K Salmela, L Fricke, J Garcia-Martinez, R Lechler, U Heemann, F Monteon, J Ortuño, J J Amenabar, M Arias, M L Nicholson, H Sperschneider, D Abendroth, C Gracida, M Lao, M S Sever, N Lameire, A Sanchez-Fructuoso, A Bascì, G Segoloni, J Connolly, P Altieri, J Akoh, H Prestele, D Girault.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267167     DOI: 10.1016/s0041-1345(00)02307-1

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  2 in total

Review 1.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

2.  Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study.

Authors:  Hussein A Sheashaa; Mohamed A Bakr; Amani M Ismail; Khaled M Mahmoud; Mohamed A Sobh; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2008-03-11       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.